The association between intravenous iron and cardiovascular complications in hemodialysis patients

Phase 3

Recruiting

• Conditions: chronic kidney disease.; Anemia in chronic kidney disease; D63.1

• Registration Number: IRCT20201108049311N1
• Lead Sponsor: Personal expense

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Be volunteer to participate in the study
Patients with end-stage renal disease that have undergone six months of their dialysis
Age group of 18-80 years

Exclusion Criteria

>700 Ferritin level and/or >40% Iron saturation
Having an active infection

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Decreasing the required weakly dose of Erythropoietin. Timepoint: Monthly during 6 month prescription of intravenous Iron. Method of measurement: Performing blood test and ELISA method.;Reducing cardiovascular events. Timepoint: Monthly during 6 month prescription of intravenous Iron. Method of measurement: Investigating the incidence of chronic myocardial ischemia, cerebral stroke, heart failure and mortality rate.